So Merck buys an earlier stage company for $300 million, when they could buy a later stage company, ADXS, for probably around $100 million but they have chosen not to or even strike a partnership deal with ADXS. What does that tell you about how they view the potential of ADXS' platform?
Yeah, the pattern more often than not is that there is no collusion between the companies and these firms, which does fly in the face of what a lot of people believe when ownership changes.
It always seems to be "someone knows something," but the movement by the investment groups almost never bears that out.
Any major good news from ADXS is also likely going to come as a blindside.